Search results for "Liver Cancer"

showing 10 items of 172 documents

The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study

2019

Background: The Italian Liver Cancer (ITA.LI.CA) prognostic system for patients with hepatocellular carcinoma (HCC) has recently been proposed and validated. We sought to explore the relationship among the ITA.LI.CA prognostic variables (ie tumour stage, functional score based on performance status and Child-Pugh score, and alpha-fetoprotein), treatment selection and survival outcome in HCC patients. Patients and Methods: We analysed 4,867 consecutive HCC patients undergoing six main treatment strategies (liver transplantation, LT; liver resection, LR; ablation, ABL; intra-arterial therapy, IAT; Sorafenib, SOR; and best supportive care, BSC) and enrolled during 2002-2015 in a multicenter It…

MaleOncologySorafenibmedicine.medical_specialtyPrognostic variableCarcinoma Hepatocellularmedicine.medical_treatmenttreatment selectionLiver transplantationhepatocellular carcinoma; prognostic variable; survival benefit; treatment selection;03 medical and health sciencesprognostic variable0302 clinical medicineInternal medicinemedicineHumanssurvival benefithepatocellular carcinoma; prognostic variable; survival benefit; treatment selectionAgedNeoplasm StagingRetrospective StudiesAged 80 and overHepatologyPerformance statusbusiness.industryLiver NeoplasmsHazard ratiohepatocellular carcinomaMiddle Agedmedicine.diseaseConfidence intervalItaly030220 oncology & carcinogenesisHepatocellular carcinomaFemale030211 gastroenterology & hepatologyLiver cancerbusinessmedicine.drug
researchProduct

Liver transplantation for hepatocellular carcinoma with intrahepatic lymphatic invasion: case reports.

2008

Multiple studies addressing liver transplantation (OLT) for hepatocellular carcinoma (HCC) have identified various prognostic determinants of tumor recurrence and decreased patient survival. However, little information is available on the impact of intrahepatic lymphatic invasion on tumor recurrence and survival after OLT for HCC. Intrahepatic lymphatic invasion was observed in 1.4% (n = 2) of liver explants with HCC in our series. Both recipients are alive without tumor recurrence at 16 and 39 months post-OLT, respectively. Intrahepatic lymphatic invasion may not be an absolute adverse prognostic factor in cases of HCC with no hilar lymph node involvement at the time of OLT.

MalePathologymedicine.medical_specialtyCarcinoma HepatocellularLymphovascular invasionmedicine.medical_treatmentLiver transplantationGastroenterologyMetastasisInternal medicinemedicineHumansNeoplasm InvasivenessLymph nodeTransplantationbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseasedigestive system diseasesLiver Transplantationsurgical procedures operativeLymphatic systemmedicine.anatomical_structureTreatment OutcomeHepatocellular carcinomaSurgeryFemaleLiver cancerbusinessTransplantation proceedings
researchProduct

Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat.

2004

Hepatocellular carcinoma represents an increasing therapeutic challenge due to its high incidence and early metastasis. Numerous studies have demonstrated the influence of the vascular system on tumor growth and development. In addition, the role of leukocyte-endothelium interaction in tumor vessels is of particular significance with regard to immunological tumor therapy. In this study we used an experimental in vivo animal model that allows a quantitative analysis on vessel morphology, microcirculation, and leukocyte-endothelium interaction. The vessel architecture in tumor tissue was found to be extremely heterogeneous, with a consecutively variable blood flow velocity. Following superfus…

MalePathologymedicine.medical_specialtyCell signalingCarcinoma HepatocellularEndotheliumPhysiologyCell CommunicationBiologyMetastasisMicrocirculationNeovascularizationmedicineLeukocytesAnimalsChemotactic FactorsNeovascularization PathologicCell adhesion moleculeMicrocirculationLiver NeoplasmsGastroenterologyHemodynamicsChemotaxismedicine.diseaseRatsRats Inbred ACImedicine.anatomical_structureLiverModels AnimalEndothelium Vascularmedicine.symptomLiver cancerCell Adhesion MoleculesBlood Flow VelocityDigestive diseases and sciences
researchProduct

Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies

2020

Multiple studies have suggested that ω-3 fatty acid intake may have a protective effect on cancer risk; however, its true association with cancer risk remains controversial. We performed an umbrella review of meta-analyses to summarize and evaluate the evidence for the association between ω-3 fatty acid intake and cancer outcomes. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to December 1, 2018. We included meta-analyses of observational studies that examined associations between intake of fish or ω-3 fatty acid and cancer risk (gastrointestinal, liver, breast, gynecologic, prostate, brain, lung, and skin) and determined the level of evidence of…

MaleRiskOncologymedicine.medical_specialty[SDV]Life Sciences [q-bio]BFMedicine (miscellaneous)ReviewCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerω-3 fatty acidMeta-Analysis as TopicNeoplasmsInternal medicineFatty Acids Omega-3medicineAnimalsHumanscancer030212 general & internal medicineω-3 fatty acid fish cancer umbrella review meta-analysischemistry.chemical_classificationfishNutrition and Dieteticsumbrella reviewbusiness.industryEndometrial cancerFishesFatty acidCancermedicine.diseaseR13. Good healthmeta-analysisObservational Studies as TopicchemistryCase-Control Studies030220 oncology & carcinogenesisMeta-analysisFemaleSkin cancerbusinessLiver cancerFood Science
researchProduct

Prognostic ability of BCLC-B subclassification in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

2018

Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Background and aims. A subclassification system for intermediate hepatocellular carcinoma (HCC) was recently proposed to optimize treatment allocation. The aim of this study was to assess the prognostic ability of that substaging proposal. Patients and methods This is a retrospective multicenter cohort study including patients with intermediate HCC treated with transarterial chemoembolization (TACE). Predictors of survival were identified using the Cox proportional regression model. Results 289 Barcelona Clinic Liver Cancer (BCLC) B patients were included. Medi…

MaleTime FactorsSpecialties of internal medicineKaplan-Meier EstimateGastroenterologyChemoembolization; Liver cancer; Radioembolization; Sorafenib; Staging system; Hepatology0302 clinical medicineRisk FactorsMedicineStage (cooking)Aged 80 and overLiver NeoplasmsGeneral MedicineMiddle AgedSorafenibTreatment OutcomeRC581-951Italy030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleChemoembolizationLiver cancerLiver cancerCohort studymedicine.drugSorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIARisk AssessmentDecision Support Techniques03 medical and health sciencesPredictive Value of TestsInternal medicineHumansChemoembolization TherapeuticRadioembolizationAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryProportional hazards modelRetrospective cohort studymedicine.diseaseStaging systemLog-rank testMultivariate Analysisbusiness
researchProduct

Selective Transarterial Chemoembolization of Advanced Hepatocellular Carcinomas: A Reasonable Palliative Option

2008

Abstract Background The purpose of this study was to provide information concerning the performance of selective transarterial chemoembolization (TACE) as a palliative treatment in patients with hepatocellular carcinoma (HCC), also in the case of multifocal lesions. Patients and methods We reviewed prospectively collected data on 43 patients with cirrhosis and HCC who underwent selective TACE as a palliative treatment. Patients were assigned to one of two groups: (1) those with one to three HCC lesions, and (2) those with four or more HCC lesions. Results One hundred and two TACE sessions were applied in 43 patients. There were 39 men and 4 women with a mean age of 65.5 ± 8.273 years. Alpha…

Malemedicine.medical_specialtyCarcinoma HepatocellularCirrhosismedicine.medical_treatmentGastroenterologyInternal medicinemedicineHumansIn patientEmbolizationChemoembolization TherapeuticAgedNeoplasm StagingRetrospective StudiesTransplantationAlpha fetoprotein levelsbusiness.industryLiver NeoplasmsPalliative CareAngiographyCancerMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationHepatocellular carcinomaFemaleSurgeryalpha-FetoproteinsTomography X-Ray ComputedbusinessLiver cancerTransplantation Proceedings
researchProduct

The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center

2019

Aims. To analyze the main etiological factors and some clinical features of patients with hepatocellular carcinoma (HCC) at diagnosis and to compare them with those we described ten years ago. Materials and Methods. We compared two groups of patients with HCC, Group 1 consisting of 132 patients (82 M, 50 F) diagnosed in the 2003–2008 period and Group 2 including 119 patients (82 M, 37 F) diagnosed in the 2013–2018 period. For all patients, age, sex, viral markers, alcohol consumption, serum alpha-fetoprotein (AFP) levels, and the main liver function parameters were recorded. The diagnosis of HCC was based on AASLD, EASL guidelines. The staging was classified according to the “Barcelona Clin…

Malemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaArticle SubjectSingle CenterGastroenterologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesEpidemiology Hepatocellular carcinoma HCV HBV NASH0302 clinical medicineRisk FactorsInternal medicineEpidemiologyHumansMedicineStaging systemAgedNeoplasm StagingGeneral Immunology and Microbiologybusiness.industryLiver NeoplasmsRGeneral MedicineHepatitis Bmedicine.diseaseHepatitis Cdigestive system diseases030220 oncology & carcinogenesisHepatocellular carcinomaEtiologyMedicineViral MarkersFemale030211 gastroenterology & hepatologyalpha-FetoproteinsLiver functionbusinessLiver cancerResearch ArticleBioMed Research International
researchProduct

Liver Transplantation for Hepatocellular Carcinoma After Yttrium Therapy: A Case Report

2008

Yttrium-90 microspheres constitute one of the most recent treatment options for hepatocellular carcinoma (HCC) in the setting of cirrhosis. As such, their spectrum of indication is not yet fully established. Herein, we have reported the case of a patient with HCC beyond the listing criteria for liver transplantation (OLT) who was treated preoperatively with selective transarterial chemoembolization and yttrium-90 microspheres. He was subsequently transplanted with a liver from an 81-year-old donor allocated through Eurotransplant as a "rescue offer." The posttransplant course was uneventful. Pathologic examination revealed a multifocal, well-differentiated pT2 tumor with no vascular invasio…

Malemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentLiver transplantationMicrospheremedicineHumansYttrium RadioisotopesChemoembolization TherapeuticAged 80 and overTransplantationbusiness.industryLiver NeoplasmsCancerTreatment optionsMiddle Agedmedicine.diseaseCombined Modality TherapyLiver TransplantationTumor recurrenceSurgeryTreatment Outcomesurgical procedures operativeHepatocellular carcinomaSurgerybusinessLiver cancerTransplantation Proceedings
researchProduct

Hepatocellular carcinoma in patients with autoimmune hepatitis.

2009

To evaluate and confirm the low incidence of hepatocellular carcinoma (HCC) in patients with autoimmune hepatitis (AIH). At present only very few cases of HCC in patients with AIH and definite exclusion of chronic viral hepatitis have been published, suggesting that HCC due to AIH is rare.In order to further investigate the incidence of HCC in patients with AIH, we reviewed our large cohort of 278 patients with AIH.Eighty-nine patients (32%) were diagnosed with liver cirrhosis, a preneoplastic condition for HCC. We studied a total of 431 patient years of cirrhosis in these patients, an average 4.8 years per patient. During this period none of the patients of our own study cohort developed H…

Malemedicine.medical_specialtyCirrhosisAsiaCarcinoma HepatocellularAutoimmune hepatitisGastroenterologyCohort StudiesHepatitis B Chronicimmune system diseasesInternal medicineMedicineHumansneoplasmsAfrica South of the SaharaAgedHepatitisbusiness.industryLiver Cirrhosis BiliaryDeveloped CountriesIncidenceLiver NeoplasmsGastroenterologyGeneral MedicineHepatitis CHepatitis BHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseasesBrief ArticlesHepatitis AutoimmuneHepatocellular carcinomaFemaleHemochromatosisbusinessLiver cancerViral hepatitisWorld journal of gastroenterology
researchProduct

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre s…

2015

Background & Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Resul…

Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularLoco-regional therapieHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyCohort StudiesLiver diseaseInterquartile rangeInternal medicinemedicineHumansBest supportive care; Cirrhosis; Hepatocellular carcinoma; Liver resection; Loco-regional therapies; Survival benefit; Aged; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Treatment Outcome; Medicine (all); HepatologyBEST SUPPORTING CAREAgedNeoplasm StagingCirrhosiHepatologyPerformance statusLiver resectionbusiness.industryMedicine (all)CIRRHOISISCarcinomaLiver NeoplasmsHepatocellularMiddle Agedmedicine.diseasePrognosisBCLC StageTreatment OutcomeCirrhosisItalySurvival benefitHepatocellular carcinomaMultivariate AnalysisFemaleLoco-regional therapiesLiver cancerbusinessBest supportive careJournal of hepatology
researchProduct